With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
The current price of Novo Nordisk A/S in the market is ₺2.028,86, with a 24-hour trading volume of ₺23,72B. The asset's market cap is ₺8,98T, after moving 2.69% in the last day.
Tokenized Novo Nordisk A/S is trading at ₺2.058,67, with a tokenized market cap of ₺1,48B and a 24-hour trading volume of ₺59,79M. The tokenized asset has moved 0.29% in the past 24 hours.